Olfactory impairment predicts cognitive decline in early Parkinson's disease

Parkinsonism and Related Disorders

Volumn 25, Issue , 2016, Pages 45-51

  Fullard, Michelle E ^a,b   Tran, Baochan ^b   Xie, Sharon X ^b   Toledo, Jon B ^b,c   Scordia, Christi ^b   Linder, Carly ^b   Purri, Rachael ^b   Weintraub, Daniel ^a,b   Duda, John E ^a,b   Chahine, Lama M ^b   Morley, James F ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cerebrospinal fluid; Mild cognitive impairment; Non motor symptoms; Olfaction; Parkinson's disease

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

ADULT; AGED; ANXIETY; ARTICLE; AUTONOMIC DYSFUNCTION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EVALUATION; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NEUROLOGIC EXAMINATION; NON-MOTOR SYMPTOM; PARKINSON DISEASE; PREDICTION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; SCORING SYSTEM; SMELLING; SMELLING DISORDER; SYMPTOM; UNIVERSITY OF PENNSYLVANIA SMELL IDENTIFICATION TEST; CEREBROSPINAL FLUID; COGNITIVE DYSFUNCTION; COHORT ANALYSIS; COMPLICATION; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; OLFACTION DISORDERS; PROPORTIONAL HAZARDS MODEL;

AGED; AMYLOID BETA-PEPTIDES; BIOMARKERS; COGNITIVE DYSFUNCTION; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OLFACTION DISORDERS; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODELS; TAU PROTEINS;

EID: 84959227747     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2016.02.013     Document Type: Article

References (34)

1. [1] Boesveldt, S., Verbaan, D., Knol, D.L., Visser, M., van Rooden, S.M., van Hilten, J.J., et al. A comparative study of odor identification and odor discrimination deficits in Parkinson's disease. Mov. Disord. 23:14 (2008), 1984–1990.
2. [2] Doty, R.L., Deems, D.A., Stellar, S., Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38:8 (1988), 1237–1244.
3. [3] Ponsen, M.M., Stoffers, D., Booij, J., van Eck-Smit, B.L., Wolters, E.C., Berendse, H.W., Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann. Neurol. 56:2 (2004), 173–181.
4. [4] Braak, H., Del Tredici, K., Rub, U., de Vos, R.A., Jansen Steur, E.N., Braak, E., Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24:2 (2003), 197–211.
5. [5] Berendse, H.W., Roos, D.S., Raijmakers, P., Doty, R.L., Motor and non-motor correlates of olfactory dysfunction in Parkinson's disease. J. Neurol. Sci. 310:1–2 (2011), 21–24.
6. [6] Chen, W., Kang, W.Y., Chen, S., Wang, Y., Xiao, Q., Wang, G., et al. Hyposmia correlates with SNCA variant and non-motor symptoms in Chinese patients with Parkinson's disease. Parkinsonism Relat. Disord. 21:6 (2015), 610–614.
7. [7] Cramer, C.K., Friedman, J.H., Amick, M.M., Olfaction and apathy in Parkinson's disease. Parkinsonism Relat. Disord. 16:2 (2010), 124–126.
8. [8] Verbaan, D., Boesveldt, S., van Rooden, S.M., Visser, M., Marinus, J., Macedo, M.G., et al. Is olfactory impairment in Parkinson disease related to phenotypic or genotypic characteristics?. Neurology 71:23 (2008 Dec 2), 1877–1882.
9. [9] Bohnen, N.I., Muller, M.L., Kotagal, V., Koeppe, R.A., Kilbourn, M.A., Albin, R.L., et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain 133:6 (2010), 1747–1754.
10. [10] Postuma, R., Gagnon, J.F., Cognition and olfaction in Parkinson's disease. Brain, 133(12), 2010 e160; author reply e161.
11. [11] Morley, J.F., Duda, J.E., Neuropsychological correlates of olfactory dysfunction in Parkinson's disease. J. Neurol. Sci. 310:1–2 (2011), 228–230.
12. [12] Damholdt, M.F., Borghammer, P., Larsen, L., Ostergaard, K., Odor identification deficits identify Parkinson's disease patients with poor cognitive performance. Mov. Disord. 26:11 (2011), 2045–2050.
13. [13] Stephenson, R., Houghton, D., Sundarararjan, S., Doty, R.L., Stern, M., Xie, S.X., et al. Odor identification deficits are associated with increased risk of neuropsychiatric complications in patients with Parkinson's disease. Mov. Disord. 25:13 (2010), 2099–2104.
14. [14] Baba, T., Kikuchi, A., Hirayama, K., Nishio, Y., Hosokai, Y., Kanno, S., et al. Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease: a 3 year longitudinal study. Brain 135:1 (2012), 161–169.
15. [15] Bibl, M., Mollenhauer, B., Esselmann, H., Lewczuk, P., Klafki, H.W., Sparbier, K., et al. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 129:5 (2006), 1177–1187.
16. [16] Compta, Y., Marti, M.J., Ibarretxe-Bilbao, N., Junque, C., Valldeoriola, F., Munoz, E., et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov. Disord. 24:15 (2009), 2203–2210.
17. [17] Siderowf, A., Xie, S.X., Hurtig, H., Weintraub, D., Duda, J., Chen-Plotkin, A., et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 75:12 (2010), 1055–1061.
18. [18] Parnetti, L., Farotti, L., Eusebi, P., Chiasserini, D., De Carlo, C., Giannandrea, D., et al. Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson's Disease. Front. Aging Neurosci., 6, 2014 Mar 31, 53.
19. [19] Parkinson Progression Marker Initiative, The Parkinson progression marker initiative (PPMI). Prog. Neurobiol. 95:4 (2011), 629–635.
20. [20] Goetz, C.G., Tilley, B.C., Shaftman, S.R., Stebbins, G.T., Fahn, S., Martinez-Martin, P., et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23:15 (2008), 2129–2170.
21. [21] Doty, R.L., Shaman, P., Dann, M., Development of the University of Pennsylvania smell identification test: a standardized microencapsulated test of olfactory function. Physiol. Behav. 32:3 (1984), 489–502.
22. [22] Nomura, T., Inoue, Y., Kagimura, T., Uemura, Y., Nakashima, K., Utility of the REM sleep behavior disorder screening questionnaire (RBDSQ) in Parkinson's disease patients. Sleep Med. 12:7 (2011), 711–713.
23. [23] Visser, M., Marinus, J., Stiggelbout, A.M., Van Hilten, J.J., Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov. Disord. 19:11 (2004), 1306–1312.
24. [24] Weintraub, D., Oehlberg, K.A., Katz, I.R., Stern, M.B., Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. Am. J. Geriatr. Psychiatry 14:2 (2006), 169–175.
25. [25] Litvan, I., Goldman, J.G., Troster, A.I., Schmand, B.A., Weintraub, D., Petersen, R.C., et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society task force guidelines. Mov. Disord. 27:3 (2012 Mar), 349–356.
26. [26] Weintraub, D., Simuni, T., Caspell-Garcia, C., Coffey, C., Lasch, S., Siderowf, A., et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Mov. Disord. 30:7 (2015 Jun), 919–927.
27. [27] Kang, J.H., Irwin, D.J., Chen-Plotkin, A.S., Siderowf, A., Caspell, C., Coffey, C.S., et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 70:10 (2013), 1277–1287.
28. [28] Bender, R., Lange, S., Adjusting for multiple testing–when and how?. J. Clin. Epidemiol. 54:4 (2001), 343–349.
29. [29] Laird, N.M., Ware, J.H., Random-effects models for longitudinal data. Biometrics 38:4 (1982), 963–974.
30. [30] Irwin, D.J., Lee, V.M., Trojanowski, J.Q., Parkinson's disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat. Rev. Neurosci. 14:9 (2013), 626–636.
31. [31] Hely, M.A., Reid, W.G., Adena, M.A., Halliday, G.M., Morris, J.G., The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23:6 (2008), 837–844.
32. [32] Compta, Y., Parkkinen, L., O'Sullivan, S.S., Vandrovcova, J., Holton, J.L., Collins, C., et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain 134:5 (2011), 1493–1505.
33. [33] Adler, C.H., Caviness, J.N., Sabbagh, M.N., Shill, H.A., Connor, D.J., Sue, L., et al. Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol. 120:6 (2010 Dec), 827–828.
34. [34] Murphy, C., Cain, W.S., Gilmore, M.M., Skinner, R.B., Sensory and semantic factors in recognition memory for odors and graphic stimuli: elderly versus young persons. Am. J. Psychol. 104:2 (1991), 161–192.